While 503B facilities are required to follow current Good Manufacturing Practices (cGMP), the compounded drugs themselves are not FDA-approved. If semaglutide and tirzepatide are removed from the 503B bulks list, the availability of compounded GLP-1s would drop significantly, Michael Snyder, MD, FACS, FASMBS, DABOM, medical director of the Bariatric Surgery Center at Rose Medical Center, founder and director of the Denver Center for Bariatric Surgery Foundation, and in-house obesity specialist at FuturHealth, told MNT
However, expectations should be realistic: biological factors driving obesity remain present and reassert themselves when pharmaceutical intervention ends
NG28 Type 2 diabetes in adults: management Initial medicines
Throughout this treatment
& Wolf, M
This effect helps protect the kidneys and slow the progression of chronic kidney disease in people with type 2 diabetes